Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Inovio Pharmaceuticals Inc chart...

About the Company

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

CEO

Jong Kim

Exchange

NASDAQ

Website

http://www.inovio.com/

$98M

Total Revenue

309

Employees

$297M

Market Capitalization

-6.55

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $INO News

Inovio Pharmaceuticals files patent for method for preparing electroporation device for treatment using charge current

2d ago, source: Pharmaceutical Technology

Prepare an electroporation device efficiently with Inovio Pharmaceuticals' patented method. Optimize charging process for treatment delivery.

Inovio Pharmaceuticals Inc INO

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inovio Pharmaceuticals Inc. Q4 Loss Narrows

21d ago, source: Business Insider

(RTTNews) - Inovio Pharmaceuticals Inc. (INO) released Loss for fourth quarter that decreased from last year The company's bottom line came in at -$25 million, or -$1.10 per share. This compares ...

Call Traders Swarm Heavily Shorted Pharma Stock

17d ago, source: SchaeffersResearch.com

Echoing this, its Schaeffer's put/call open interest ratio (SOIR) sits higher than 97% of annual readings, indicating ...

Q4 2023 Inovio Pharmaceuticals Inc Earnings Call

21d ago, source: Yahoo Finance

Thomas Hong; IR; INOVIO Pharmaceuticals, Inc. Jacqueline Shea; President & CEO; INOVIO Pharmaceuticals, Inc. Michael Sumner; Chief Medical Officer; INOVIO ...

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

21d ago, source: Finanznachrichten

INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. to evaluate the combination of INO-3112 and LOQTORZI as a potential treatment for patients with ...

Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript

21d ago, source: Seeking Alpha

Good afternoon, ladies and gentlemen and welcome to the INOVIO Fourth Quarter and Year-End 2023 Financial Results Conference Call. At this time all lines are in a listen-only mode. Following the ...

INO Inovio Pharmaceuticals, Inc.

5d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Q4 2023 Inovio Pharmaceuticals Inc Earnings Call

21d ago, source: Yahoo Finance

Q4 2023 Inovio Pharmaceuticals Inc Earnings Call Q4 2023 Inovio Pharmaceuticals Inc Earnings Call HOME MAIL NEWS FINANCE SPORT CELEBRITY STYLE WEATHER MORE... Yahoo Finance Sign in Mail Sign in to ...

Inovio Pharmaceuticals Inc.

13d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...